Aspergillosis Treatment Market Size, Share & Trends Analysis Report By Disease Type, By Drug Class, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2023 to 2030

曲霉病治疗市场预计将增长at a moderate CAGR during the forecast period. Increasing prevalence of target disease and increasing focus on the development of novel drugs is expected to positively contribute to market growth. According to Center for Disease Control and Prevention (CDC), about 2.5% of general population who have asthma also have allergic bronchopulmonary aspergillosis (ABPA), which accounts 4.8 million people worldwide. Increasing prevalence of the disease, increases demand for medicines used for the condition in the coming years.

The space has a substantial availability of medications that are reasonably priced, have good tolerance and safety profile, and few side effects that are driving the market growth. The recommended treatment for allergic aspergillosis includes Itraconazole and corticosteroids. Furthermore, the treatment for invasive type of the disease includes Voriconazole, Posaconazole, Caspofungin, and Micafungin. Surgery to remove fungal mass and embolization are used as treatment option in cases where the fungal infection causes lung bleeding.

Newer drug classes are being explored and studied for the treatment of aspergillosis. For instance, Amplyx Pharmaceuticals’ Fosmanogepix, which is a first in class drug currently in the Phase 2 clinical trials. The drug works by inhibiting the fungal enzyme Gwt1. Another drug Olorofim developed by F2G is currently in phase 3 clinical trials for invasive type of the infection. in August 2022, the company received USD 70 million financing for the development and commercialization of the drug.

Aspergillosis treatment market is segmented by drug class as:

• Corticosteroids

• Antifungal drugs

  • Azoles

  • Echinocandins

  • Others

• Others

Key market players are making strategic initiatives such as new product launch, partnerships, collaborations, and licensing agreements, accelerating the market growth. For instance, in May 2022, F2G Ltd and Shionogi & Co., Ltd entered into a strategic collaboration to develop and commercialize the new antifungal agent olorofim for invasive aspergillosis (IA) in Asia and Europe. This collaboration was expected to support the commercialization and expansion of the drug across the global market.

Aspergillosis Treatment Market Segmentation

Major companies operating in the aspergillosis treatment drugs space include Pfizer, Inc.; Merck & Co. Inc; F2G; Novartis AG; Astellas Pharma Inc;Bayer AG; Mayne Pharma Group Limited; and PULMATRiX, Inc. amongst others.